Clinical trial · Observational
Feasibility Clinical Study of Targeted and Genome-Wide Sequencing
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research is being done to find out what types of gene mutations are present in people with cancer. This study is designed to help researchers and doctors understand more about cancer. With this information, doctors may have a better idea as to which cancer treatments are most appropriate for certain patients. The information will also help researchers find out the how to identify genes in cancers from biopsies and blood samples and how to use this information to help doctors and patients make treatment decisions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sample Collection for Genome-Wide Sequencing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Solid Tumor Cancer
- interventionNames
- Other: Sample Collection for Genome-Wide Sequencing
Primary outcomes (1)
- measure
- Time From Patient Recruitment to Final Results ≤ 21 Days in ≥ 90% of Patients
- timeFrame
- All patients will be followed for up to 2 years from study enrolment, or death, or whichever event occurs first.
- description
- Average and range of time (in calendar days) that occurred between study participants providing informed consent to the reporting of genomic results to the physician.
Secondary outcomes (3)
- measure
- Number of Participants With Actionable Genomic Results
- timeFrame
- All patients will be followed for up to 2 years from study enrolment, or death, or whichever event occurs first.
- description
- Number of participants with actionable genomic results (defined as having the potential to impact on management recommendations based on diagnostic, prognostic and/or predictive implications), expressed as a percentage of the total number of study participants.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years. * Histological or cytological proof of solid tumour cancer. * At least one biopsiable lesion deemed medically accessible and safe to biopsy. * Candidate for one or more phase I or II clinical trials in the local institution or in another Ontario institution, at the time of study enrollment or at a later time point. * Fulfills local institution's laboratory parameters for tumor biopsy. * Willingness and ability of patient to provide signed voluntary informed consent. Exclusion Criteria: * Any condition that could interfere with their ability to provide informed consent such as dementia or severe cognitive impairment. * Any contraindication to undergoing a biopsy procedure.
References
Publications (0)
Data not yet available